Methylphenidate XR ARX (Methylphenidate)
methylphenidate hydrochloride 36 mg modified release tablet, 30 · ORAL · PBS code 2388Q
AUTHORITY_REQUIREDWhat it costs
AU$37.91 PBS-determined price per 30 units
Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.
- • First listed on the PBS: 2021-12-01.
- • Repeats: 5.
- • PBS program: GE.
Eligibility criteria for subsidised access
The following is the government's own wording from the PBS Schedule, shown unchanged.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Attention deficit hyperactivity disorder
Patient must have demonstrated a response to immediate-release methylphenidate hydrochloride with no emergence of serious adverse events; AND
Patient must require continuous coverage over 12 hours; AND
The treatment must not exceed a maximum daily dose of 72 mg of PBS-subsidised treatment with this drug; AND
Patient must be or have been diagnosed between the ages of 6 and 18 years inclusive; AND
Must be treated by a health practitioner who is any of: (i) a medical practitioner, (ii) a nurse practitioner who is continuing treatment with this medicine (of any strength) that was initiated by a medical practitioner as a PBS benefit.
Sponsor: Arrotex Pharmaceuticals Pty Ltd ABN 30 605 552 234
Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.